Table 1.
Clinical Trials by Major Pharma/Biotech Companies.
| Sponsors/Collaborators | NCT Trial Number | Target Antigen | Agent | Targeted Tumor Type | Stage |
|---|---|---|---|---|---|
| Medigene | NCT03503968 | PRAME | MDG1011 | Unknown | Phase I/II |
| Bellicum Pharmaceuticals | NCT02743611 | PRAME | BPX-701 | AML, myelodysplastic syndrome | Phase I |
| Kite Pharma | NCT03139370 | MAGE-A3/A6 | KITE-718 | Unknown | Phase I |
| Immatics | NCT03247309 | Unknown | IMA-201 | Head and neck squamous cell carcinoma, squamous cell NSCLC | Phase I |
| Adaptimmune | NCT02592577 | MAGE-A10 | MAGE-A10c796T | NSCLC | Phase I |
| Adaptimmune | NCT01343043 | NY-ESO-1 | NY-ESO-1c259T | Synovial sarcoma | Phase I/II |
| Adaptimmune | NCT01892293 | NY-ESO-1 | NY-ESO-1c259T | Multiple myeloma | Phase I/II |
| Adaptimmune | NCT01352286 | NY-ESO-1 | NY-ESO-1c259T | Multiple myeloma | Phase I/II |
| Adaptimmune | NCT01567891 | NY-ESO-1 | NY-ESO-1c259T | Ovarian cancer | Phase I/II |
| Adaptimmune | NCT01350401 | NY-ESO-1 | NY-ESO-1c259T | Melanoma | Phase I/II |
| Adaptimmune | NCT02588612 | NY-ESO-1 | NY-ESO-1c259T | NSCLC | Phase I/II |
| Adaptimmune | NCT03132792 | AFP | AFPc332T | Hepatocellular cancer | Phase I |
| Adaptimmune | NCT03168438 | NY-ESO-1 | NY-ESO-1c259T | Refractory multiple myeloma | Phase I |
| Adaptimmune | NCT02989064 | MAGE-A10 | MAGE-A10c796T | Urinary bladder cancer, head and neck cancer, melanoma | Phase I |
Abbreviations: AFP, α-fetoprotein; AML, acute myeloid leukemia; MAGE, melanoma-associated antigen; NSCLC, non-small cell lung carcinoma; PRAME, preferentially expressed antigen in melanoma.